News | Computed Tomography (CT) | October 14, 2021

Cardiac CTA Parameters Predict Post-TAVR Mortality

Cardiac CTA derived left atrium emptying fraction (LAEF) improves predictive performance of established clinical risk scores and may be used to assess TAVR patient risk during pre-procedure workup and post-procedural surveillance. These images show LAVmax (A and B), LAVmin (C and D), and LAEF using cardiac CTA. LAEF was calculated as (LAVmax-LAVmin)/LAVmax x 100. Given LAVmax of 109 mL and LAVmin of 80 mL, the LAEF was calculated to be 27%.  Image courtesy of AJR.

Cardiac CTA derived left atrium emptying fraction (LAEF) improves predictive performance of established clinical risk scores and may be used to assess TAVR patient risk during pre-procedure workup and post-procedural surveillance. These images show LAVmax (A and B), LAVmin (C and D), and LAEF using cardiac CTA. LAEF was calculated as (LAVmax-LAVmin)/LAVmax x 100. Given LAVmax of 109 mL and LAVmin of 80 mL, the LAEF was calculated to be 27%. Image courtesy of AJR.


October 14, 2021 — Cardiac computed tomography angiography (CTA) derived left atrium emptying fraction (LAEF) improves predictive performance of established clinical risk scores and may be used to assess patients’ risk during pre-transcatheter aortic valve replacement (TAVR) workup and post-procedural surveillance. This is according to a new study published in the American Roentgen Ray Society (ARRS) American Journal of Roentgenology (AJR).[1]

“LAEF derived from preprocedural cardiac CTA independently predicts mortality in patients with severe aortic stenosis undergoing TAVR,” concluded corresponding author Joseph Schoepf, M.D., from the Medical University of South Carolina’s Heart and Vascular Center.

Aortic stenosis (AS) is an obstructive valvular disorder associated with changes in the left ventricle (LV) and left atrium (LA). Chronically elevated LV pressures lead to LV myocardial hypertrophy and fibrosis, which consequently lead to LA enlargement and remodeling to maintain adequate filling of the LV. These changes in the LA function can be used as an early indicator of atrial remodeling and can be demonstrated by reduced LAEF, and increased maximum (LAVmax) and minimum (LAVmin) LA volume. The authors of the study said parameters of LA function are most commonly assessed using transthoracic echocardiography (TTE), but can also be evaluated with cardiac MRI and cardiac CCTA. In patients with severe AS undergoing TAVR, LA dilatation assessed by TTE is associated with poor outcome, which raised the question if CTA could be used to assess TAVR patients.

CT is already required for preprocedural workup of patients undergoing TAVR and provides not only information on the arterial access route, but also anatomic and morphologic assessment of the aortic valve for annular prosthesis sizing, positioning of the valve and determination of risk of annular injury or coronary occlusion. Information on preprocedural CTA can also provide information on volumes and function of the LA with appropriate post-processing and this study looked at whether the data could be leveraged to predict outcomes in patients undergoing TAVR.

Schoepf and colleagues’ retrospective single-center study included 175 patients with severe aortic stenosis (92 male, 83 female; median age, 79 years) who underwent cardiac CTA for clinical pre-TAVR assessment. Maximum and minimum left atrium volumes were calculated using biplane area-length measurements, and the values were indexed to body surface area: LAVImax and LAVImin, respectively.

In their sample, a reduced LAEF independently predicted all-cause mortality within 24 months post-procedure (hazard ratio 0.97 [0.94–0.99]; p=.02). Moreover, when incorporating LAEF, the c-index of the Society of Thoracic Surgeons Predicted Risk of Mortality significantly increased from 0.64 to 0.70.

Acknowledging that atrial parameters are more commonly assessed using transthoracic echocardiography, both atrial volume and atrial function can be reliably assessed using cardiac CTA, “which now represents the gold standard for preprocedural planning in patients undergoing TAVR,” the authors of this AJR article added.

For more information: arrs.org

Reference:

1. Gilberto J. Aquino, Josua A. Decker, U. Joseph Schoepf, et al. Utility of Functional and Volumetric Left Atrial Parameters Derived From Preprocedural Cardiac CTA in Predicting Mortality After Transcatheter Aortic Valve Replacement. AJR. Oct 13 [published online]. Accepted manuscript. doi:10.2214/AJR.21.26775.


Related Content

News | Computed Tomography (CT)

Feb. 2, 2026 — GE HealthCare has announced that Allia Moveo has received U.S. Food and Drug Administration (FDA) 510(k) ...

Home February 02, 2026
Home
News | Computed Tomography (CT)

Jan. 6, 2026 — Cleerly, a leader in AI-based cardiovascular imaging, has announced that Aetna will begin covering ...

Home January 07, 2026
Home
News | Computed Tomography (CT)

Dec. 2, 2025 — At RSNA 2025, Siemens Healthineers announced Syngo.CT Coronary Cockpit1, a new software solution within ...

Home December 03, 2025
Home
News | Computed Tomography (CT)

Nov. 18, 2025 — Harrison.ai has launched its CE-marked CT Chest solution, a comprehensive AI tool that assists ...

Home November 18, 2025
Home
News | Computed Tomography (CT)

Sept. 30, 2025 — Biograph and Caristo Diagnostics have announced a partnership for Biograph to become the first U.S ...

Home October 02, 2025
Home
News | Computed Tomography (CT)

Sept. 29, 2025 — Many studies have shown the inverse relationship between bone mineral density (BMD) — the gold standard ...

Home September 30, 2025
Home
News | Computed Tomography (CT)

June 30, 2025 — Heartflow, Inc., a provider of AI technology for coronary artery disease (CAD), will present new data ...

Home July 08, 2025
Home
News | Computed Tomography (CT)

May 19, 2025 - Arineta, a provider of cardiovascular imaging solutions, recently announced that its SpotLight Duo ...

Home May 19, 2025
Home
News | Computed Tomography (CT)

Mar. 28, 2025 — At the American College of Cardiology (ACC) 2025 meeting, GE HealthCare will introduce Revolution Vibe,i ...

Home March 28, 2025
Home
News | Computed Tomography (CT)

March 11, 2025 — Caristo Diagnostics has received U.S. Food and Drug Administration (FDA) 510(k) clearance of its CaRi ...

Home March 11, 2025
Home
Subscribe Now